Lite Strategy’s Litecoin results show $16M in net income as LTC rises 60%

Lite Strategy’s Litecoin-driven results showed $16.0 million in net income for its fiscal 2027 first quarter, as a 60% rise in LTC lifted the value of its treasury holdings. In results released on November 10, 2026, for the quarter ended September 30, 2026, the company also reported fewer shares outstanding, lower operating costs and no debt.

Key takeaways

• Lite Strategy cut its share count by 6.8% through quarterly buybacks.
• Quarter-end holdings totaled 751,798 LTC, valued at $50.5 million.
• Operating cash use fell 52% from the year-earlier quarter.
• The company is investing in LitVM while pursuing Litecoin-focused partnerships and acquisitions.

Lite Strategy’s results reflect Litecoin gains and treasury income

Lite Strategy attributed most of its quarterly profit to revaluing its LTC holdings following Litecoin’s 60% appreciation. The quarter opened its second fiscal year under the Litecoin treasury strategy, which it adopted in 2025.

The Nasdaq-listed company, trading as LITS, repurchased approximately 2.2 million shares at an average of $1.08 each during the quarter. It reported buying at a discount to net asset value in the low 20% range. By September 30, 2026, aggregate repurchases since the program began represented approximately 18% of shares.

Buybacks continued in October 2026, with another 825,181 shares purchased at a weighted-average price of $1.27. Shares outstanding stood at 29,884,653 on October 30, 2026.

The covered call program produced approximately $130,000 in quarterly premiums, taking cumulative proceeds to about $1.1 million in slightly more than a year. Lite Strategy said active treasury operations supplied all funding for its repurchases, while its balance sheet remained debt-free.

General and administrative spending declined 24% to $2.4 million. Net cash consumed by operations fell 52% to $2.2 million against the comparable year-earlier quarter.

At September 30, 2026, the company held 751,798 LTC worth $50.5 million, including 64,700 LTC pledged to secure covered call options. Cash and cash equivalents totaled $4.3 million, alongside $46.2 million in unrestricted digital assets. Total assets were $58.4 million, compared with $1.7 million in liabilities.

Regulatory classification and LitVM investment

Lite Strategy’s update cited the SEC’s March 2026 Digital Asset Interpretation, which classified Litecoin as a digital commodity rather than a security. The CFTC confirmed it would continue regulating LTC on that basis, the company said.

The SEC subsequently proposed Regulation Crypto Assets in August 2026; public comments closed on October 20, 2026. According to Lite Strategy, these developments provided corporate treasuries, asset managers and other institutions with a clearer basis for assessing LTC exposure.

Beyond holding the token, the company is the lead institutional investor in LitVM, a zero-knowledge Layer-2 platform developing smart contract functionality for Litecoin. LitVM is advancing toward its mainnet launch.

The platform is designed to support decentralized finance, stablecoin issuance and tokenized assets, using LTC as its native token. Litecoin creator and Lite Strategy board member Charlie Lee described the network as expanding beyond payments through smart contracts and regulatory recognition.

Fiscal 2027 priorities and pharmaceutical assets

Lite Strategy’s priorities center on increasing the LTC backing each common share through selective acquisitions, strategic partnerships and disciplined capital deployment. Management also plans to broaden its institutional investor base during fiscal 2027.

CEO and CFO Jay File said capital allocation decisions are assessed against their expected contribution to value per share. Alongside its Litecoin results, Lite Strategy outlined plans to build operating activity across that ecosystem, supported by its established custody arrangements, internal controls, and SEC and Nasdaq compliance.

The company also continues preclinical work on voruciclib, an oral CDK9 inhibitor, for non-oncology indications. Preliminary ex vivo studies showed changes in immune cell subsets that supported further development in animal models. It is evaluating licensing or sale opportunities for both voruciclib and zandelisib as potential sources of non-dilutive capital.

Article produced with the assistance of artificial intelligence and reviewed by the editorial team.